The domestic pharmaceutical and bio-industry has made a bid into the development of new drugs for pancreatic cancer through the use of combination therapy. Despite the development of various treatments to date, the five-year survival rate of pancreatic cancer has remained the lowest among the top 10 cancers, at 12.6%. Pancreatic cancer is difficult to detect early due to its organ location and is known for its poor prognosis.

Domestic pharma and biotech companies have chosen 'combination therapy' as a strategy to improve the treatment effect of its pancreatic cancer treatments while reducing the side effects of existing platinum-based chemotherapy. Currently, NeoImmuneTech, CG Invites, MedPacto, and Presti